Sands Capital Ventures
Latest statistics and disclosures from Sands Capital Ventures's latest quarterly 13F-HR filing:
- Top 5 stock holdings are KVYO, NU, DASH, IKT, CPNG, and represent 73.98% of Sands Capital Ventures's stock portfolio.
- Added to shares of these 9 stocks: IKT (+$36M), CPNG (+$20M), NU (+$16M), DDOG (+$14M), MNDY (+$11M), IOT (+$8.5M), TOST (+$8.3M), CRWD (+$5.8M), PATH (+$5.5M).
- Started 2 new stock positions in MNDY, IKT.
- Reduced shares in these 6 stocks: SNOW (-$11M), DASH, KVYO, BIOA, GTLB, SPRB.
- Sold out of its position in GTLB.
- Sands Capital Ventures was a net buyer of stock by $108M.
- Sands Capital Ventures has $460M in assets under management (AUM), dropping by 29.22%.
- Central Index Key (CIK): 0001846444
Tip: Access up to 7 years of quarterly data
Positions held by Sands Capital Ventures consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Sands Capital Ventures
Sands Capital Ventures holds 21 positions in its portfolio as reported in the December 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Klaviyo Com Ser A (KVYO) | 31.1 | $143M | 3.5M | 41.24 |
|
|
| Nu Hldgs Ord Shs Cl A (NU) | 15.8 | $73M | +27% | 7.0M | 10.36 |
|
| Doordash Cl A (DASH) | 14.9 | $68M | -3% | 407k | 167.75 |
|
| Inhibikase Therapeutics Com New (IKT) | 7.7 | $36M | NEW | 11M | 3.25 |
|
| Coupang Cl A (CPNG) | 4.4 | $20M | +7650% | 925k | 21.98 |
|
| Uipath Cl A (PATH) | 4.4 | $20M | +37% | 1.6M | 12.71 |
|
| Datadog Cl A Com (DDOG) | 3.0 | $14M | +6855% | 98k | 142.89 |
|
| Acrivon Therapeutics Common Stock (ACRV) | 2.8 | $13M | 2.1M | 6.02 |
|
|
| Monday SHS (MNDY) | 2.5 | $11M | NEW | 48k | 235.44 |
|
| Tarsus Pharmaceuticals (TARS) | 2.0 | $9.4M | 170k | 55.37 |
|
|
| Samsara Com Cl A (IOT) | 1.9 | $8.7M | +6163% | 199k | 43.69 |
|
| Toast Cl A (TOST) | 1.8 | $8.4M | +5099% | 232k | 36.45 |
|
| 10x Genomics Cl A Com (TXG) | 1.5 | $6.9M | 482k | 14.36 |
|
|
| Snowflake Cl A (SNOW) | 1.3 | $6.0M | -63% | 39k | 154.41 |
|
| Acumen Pharmaceuticals (ABOS) | 1.3 | $5.9M | 3.4M | 1.72 |
|
|
| Crowdstrike Hldgs Cl A (CRWD) | 1.3 | $5.9M | +7637% | 17k | 342.16 |
|
| Bioage Labs (BIOA) | 1.0 | $4.6M | -27% | 786k | 5.79 |
|
| Candel Therapeutics (CADL) | 0.8 | $3.5M | 406k | 8.68 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.3 | $1.3M | 725k | 1.73 |
|
|
| 908 Devices (MASS) | 0.1 | $522k | 237k | 2.20 |
|
|
| Spruce Biosciences (SPRB) | 0.1 | $301k | -9% | 716k | 0.42 |
|
Past Filings by Sands Capital Ventures
SEC 13F filings are viewable for Sands Capital Ventures going back to 2021
- Sands Capital Ventures 2024 Q4 filed Feb. 13, 2025
- Sands Capital Ventures 2024 Q3 filed Nov. 13, 2024
- Sands Capital Ventures 2024 Q1 filed May 14, 2024
- Sands Capital Ventures 2023 Q3 filed Nov. 14, 2023
- Sands Capital Ventures 2023 Q2 filed Aug. 15, 2023
- Sands Capital Ventures 2023 Q1 filed May 12, 2023
- Sands Capital Ventures 2022 Q4 filed Feb. 13, 2023
- Sands Capital Ventures 2022 Q3 filed Nov. 9, 2022
- Sands Capital Ventures 2022 Q2 filed Aug. 12, 2022
- Sands Capital Ventures 2022 Q1 filed May 13, 2022
- Sands Capital Ventures 2021 Q4 filed Jan. 21, 2022
- Sands Capital Ventures 2021 Q3 restated filed Nov. 12, 2021
- Sands Capital Ventures 2021 Q3 filed Nov. 4, 2021